223 related articles for article (PubMed ID: 18721250)
1. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.
Pai SA; Shetty R
Acta Ophthalmol; 2009 Nov; 87(7):806-7. PubMed ID: 18721250
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy for polypoidal choroidal vasculopathy.
Chhablani JK
Am J Ophthalmol; 2010 Nov; 150(5):754-5; author reply 755. PubMed ID: 21036213
[No Abstract] [Full Text] [Related]
5. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
6. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
Kim SJ; Yu HG
Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
[TBL] [Abstract][Full Text] [Related]
8. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
9. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
10. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
11. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for choroidal neovascularization related to inflammatory diseases.
Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R
Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273
[TBL] [Abstract][Full Text] [Related]
13. LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Park DH; Kim IT
Retina; 2012 Feb; 32(2):299-307. PubMed ID: 21817962
[TBL] [Abstract][Full Text] [Related]
14. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy.
Ghajarnia M; Kurup S; Eller A
Semin Ophthalmol; 2007; 22(2):127-31. PubMed ID: 17564935
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab.
Lucas RS; McKee HD; Lee LR
Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
[No Abstract] [Full Text] [Related]
19. Photoreceptor reconstitution correlates with visual improvement after intravitreal bevacizumab treatment of choroidal neovascularization secondary to traumatic choroidal rupture.
Francis JH; Freund KB
Retina; 2011 Feb; 31(2):422-4. PubMed ID: 21240036
[No Abstract] [Full Text] [Related]
20. Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma.
Khan MA; DeCroos FC; Storey PP; Shields JA; Garg SJ; Shields CL
Retina; 2014 Sep; 34(9):1750-6. PubMed ID: 24936941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]